⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Official Title: A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)

Study ID: NCT03693300

Interventions

Durvalumab

Study Description

Brief Summary: This is a Phase II, open-label, multi-centre study to determine the safety of a fixed dose of Durvalumab (MEDI4736) (1500 mg) every 4 weeks \[q4w\] in participants with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), who have not progressed following platinum-based sequential chemoradiation therapy (sCRT). This study will be conducted in Europe and North America.

Detailed Description: This is a Phase II, open-label, multi-centre study to determine safety of a fixed dose of Durvalumab (MEDI4736) (1500 mg) monotherapy in participants with unresectable Stage III NSCLC who have not progressed following definitive, platinum-based sCRT. Approximately, 150 participants will be treated with the study drug in Europe and North America. Participants will be in complete response (CR), partial response (PR), or have stable disease (SD) following definitive, platinum-based sCRT, as assessed by the Investigator and further supported by the screening imaging radiological assessment. Participants must not have progressed following definitive, platinum-based sCRT; radiation therapy must be completed within 42 days prior to first Investigational product (IP) dose administration. Participants must have histologically- or cytologically-documented NSCLC and locally-advanced, unresectable Stage III disease. Participants will be treated with the study drug in 2 cohorts: approximately 100-120 participants in the World Health Organization/Eastern Cooperative Oncology Group Performance Status (WHO/ECOG PS) 0 to 1 Cohort and up to 30 participants in the WHO/ECOG PS 2 Cohort.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Research Site, Gainesville, Georgia, United States

Research Site, Knoxville, Tennessee, United States

Research Site, Creteil, , France

Research Site, Paris Cedex 05, , France

Research Site, Saint Priest en Jarez, , France

Research Site, Toulouse Cedex 9, , France

Research Site, Gauting, , Germany

Research Site, Großhansdorf, , Germany

Research Site, Hamm, , Germany

Research Site, Hannover, , Germany

Research Site, Heidelberg, , Germany

Research Site, Avellino, , Italy

Research Site, Meldola, , Italy

Research Site, Milano, , Italy

Research Site, Monza, , Italy

Research Site, Parma, , Italy

Research Site, Roma, , Italy

Research Site, Barcelona, , Spain

Research Site, Guadalajara, , Spain

Research Site, Madrid, , Spain

Research Site, Sevilla, , Spain

Research Site, Valencia, , Spain

Research Site, Leeds, , United Kingdom

Research Site, Manchester, , United Kingdom

Research Site, Middlesbrough, , United Kingdom

Research Site, Nottingham, , United Kingdom

Research Site, Sheffield, , United Kingdom

Research Site, Stoke on Trent, , United Kingdom

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: